NCT01404988

Brief Summary

In the VIP (Veterans Intensive Personalized) Treatment in Heart Failure Study we will assess 2 novel interventions to enhance adherence and improve quality of life in veterans with heart failure. This 3-arm randomized controlled trial will base one active arm on how ready patients are for change in terms of diet and medication adherence and will tailor the intervention based on this. The other active arm will also assess how ready patients are for change, but will also include tailoring based on availability of environment resources, such as proximity to health food stores or social support, to further tailor the intervention. The last active arm is simply an attention group where patients will receive general health counseling in addition to background care that all patients receive. The overarching hypothesis is that the tailored interventions will lower heart failure (HF) recurrence and improve quality of life by better medication and diet adherence compared to attention placebo.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
99

participants targeted

Target at P50-P75 for not_applicable heart-failure

Timeline
Completed

Started Nov 2011

Typical duration for not_applicable heart-failure

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 27, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 28, 2011

Completed
3 months until next milestone

Study Start

First participant enrolled

November 1, 2011

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
12 months until next milestone

Results Posted

Study results publicly available

May 25, 2015

Completed
Last Updated

May 25, 2015

Status Verified

May 1, 2015

Enrollment Period

2.1 years

First QC Date

July 27, 2011

Results QC Date

February 23, 2015

Last Update Submit

May 6, 2015

Conditions

Keywords

Heart FailureTelemedicineMedication Adherence

Outcome Measures

Primary Outcomes (1)

  • Medication Adherence (Refill Compliance for All HF Medications)

    Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take. At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days. This number is referred to as the "Days Supply" and can be calculated by dividing the number of pills prescribed by the number of pills taken per day. To calculate compliance, the "Days Supply" is subtracted by the number of days between Actual Refill dates, a time span referred to as the "Days Passed". If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent. This absolute value is referred to as a "Gap". The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.

    6 months from baseline visit

Secondary Outcomes (3)

  • Adherence to ACE Inhibitors and ARB

    6 months after baseline

  • Adherence to Beta Blockers

    6 months from baseline

  • Self-reported Medication Adherence

    6 months from baseline

Study Arms (3)

Telephone-Delivered BI

EXPERIMENTAL

Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.

Behavioral: Telephone-Delivered BI

Telephone-Delivered BEI

EXPERIMENTAL

Behavioral \& Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring. Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities. Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support. Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.

Behavioral: Telephone-Delivered BEI

Telephone-Delivered API

PLACEBO COMPARATOR

Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.

Other: Telephone-Delivered API

Interventions

Behavioral Intervention will be delivered over the phone.

Telephone-Delivered BI

Behavioral and Environmental Intervention will be delivered over the phone

Telephone-Delivered BEI

Attention Placebo Intervention will be delivered over the phone

Telephone-Delivered API

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men and women (21 years) with history and clinical findings of chronic, stable HF of NYHA functional class I (previously symptomatic/now asymptomatic), II, or III.
  • They must have an available phone and 2 clinic visits in the previous 1.5 years.

You may not qualify if:

  • Patients with poor short-term survival (\< 1 year)
  • recent major surgery (\< 3 months)
  • temporarily in the area
  • or those unable to provide consent will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

VA New York Harbor Health Care System

New York, New York, 10010, United States

Location

MeSH Terms

Conditions

Heart FailureMedication Adherence

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Results Point of Contact

Title
Sundar Natarajan, MD, M.Sc.
Organization
VA New York Harbor Healthcare System

Study Officials

  • Sundar Natarajan, MD MSc

    VA New York Harbor Health Care System

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 27, 2011

First Posted

July 28, 2011

Study Start

November 1, 2011

Primary Completion

December 1, 2013

Study Completion

June 1, 2014

Last Updated

May 25, 2015

Results First Posted

May 25, 2015

Record last verified: 2015-05

Locations